

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MANNK.022C1	APPLICATION NO. Unassigned 10777053
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Simard, et al.	
	FILING DATE Concurrently herewith	GROUP Unassigned 1644

U.S. PATENT DOCUMENTS							
PV	1.	4,439,199	03/27/84	Amkraut et al.			
	2.	4,683,199	07/1987	Palladino			
	3.	4,937,190	06/26/90	Palmenberg et al.			
	4.	5,093,242	03/03/92	Bachmair et al.			
	5.	5,132,213	06/21/92	Bachmair et al.			
	6.	5,168,062	12/01/92	Stinski			
	7.	5,258,294	11/02/93	Boyle, et al.			
	8.	5,385,839	01/31/95	Stinski			
	9.	5,405,940	04/11/95	Boon et al.			
	10.	5,478,556	12/26/95	Elliot et al.			
	11.	5,487,974	01/30/96	Boon-Falleur et al.			
	12.	5,496,721	03/05/96	Bachmair et al.			
	13.	5,519,117	05/21/96	Wolfel et al.			
	14.	5,530,096	06/25/96	Wolfel et al.			
	15.	5,554,506	09/10/96	Van der Bruggen et al.			
	16.	5,554,724	09/10/96	Melief et. al.			
	17.	5,558,995	09/24/96	Van der Bruggen et al.			
	18.	5,580,859	12/03/96	Felgner et al.			
	19.	5,585,461	12/17/96	Townsend et al.			
	20.	5,589,466	12/31/96	Felgner et al.			
	21.	5,646,017	07/08/97	Bachmair et al.			
	22.	5,648,226	07/15/97	Van den Eynde et al.			
	23.	5,679,647	10/21/97	Carson et al.			
	24.	5,698,396	12/16/97	Pfreundschuh			
	25.	5,733,548	03/31/98	Restifo et al.			
	26.	5,744,316	04/28/98	Lethe et al.			
	27.	5,747,269	05/05/98	Rammensee et al.			
✓	28.	5,844,075	12/01/98	Kawakami, et al.			

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MANNK.022C1	APPLICATION NO. Unassigned 10777053
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Simard, et al.	
		FILING DATE Concurrently herewith	GROUP Unassigned 1644

U.S. PATENT DOCUMENTS							
PV	29.	5,846,540	12/08/98	Restifo et al.			
	30.	5,847,097	12/08/98	Bachmair et al.			
	31.	5,856,187	01/05/99	Restifo et al.			
	32.	5,925,565	07/20/99	Berlioz et al.			
	33.	5,962,428	10/05/99	Carrano et al.			
	34.	5,989,565	11/23/99	Storkus et al.			
	35.	5,993,828	11/30/99	Morton			
	36.	5,994,523	11/30/99	Kawakami et al.			
	37.	6,004,777	12/21/99	Tartaglia et al.			
	38.	6,008,200	12/28/99	Krieg			
	39.	6,037,135	03/14/00	Kubo et al.			
	40.	6,060,273	05/09/00	Dirks et al.			
	41.	6,074,817	06/13/00	Tartaglia et al.			
	42.	6,130,066	10/10/00	Tartaglia et al.			
V	43.	6,287,569	09/11/01	Kipps et al.			

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
PV	44.	2,147,863	05/26/94	Canada				
	45.	74899	08/13/97	Ireland				
	46.	DE 44 23 392 A1	01/11/96	Germany				
	47.	EP 1118860 A1	07/25/01	European Patent Office				
	48.	EP 1181314 A1	02/27/02	European Patent Office				
	49.	EP 93/03175	04/06/95	Patent Cooperation Treaty (Verified Translation)			X	
	50.	WO 00/06723 A1	02/10/00	Patent Cooperation Treaty				
	51.	WO 00/29008 A2	05/25/00	Patent Cooperation Treaty				
	52.	WO 00/40261 A2	07/13/00	Patent Cooperation Treaty				
V	53.	WO 00/52157 A1	09/08/00	Patent Cooperation Treaty				

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MANNK.022C1	APPLICATION NO. Unassigned 10777053
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Simard, et al.	
		FILING DATE Concurrently herewith	GROUP Unassigned 1644

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
PV	54.	WO 00/52451 A1	09/08/00	Patent Cooperation Treaty				
	55.	WO 00/66727 A1	11/09/00	Patent Cooperation Treaty				
	56.	WO 00/71158 A1	11/30/02	Patent Cooperation Treaty				
	57.	WO 00/73438 A1	12/07/00	Patent Cooperation Treaty				
	58.	WO 01/090197 A1	11/2001	Patent Cooperation Treaty				
	59.	WO 01/11040 A1	02/15/01	Patent Cooperation Treaty				
	60.	WO 01/18035 A2	03/15/01	Patent Cooperation Treaty				
	61.	WO 01/19408 A1	03/22/01	Patent Cooperation Treaty				
	62.	WO 01/23577 A3	04/05/01	Patent Cooperation Treaty				
	63.	WO 01/58478 A1	08/16/01	Patent Cooperation Treaty				
	64.	WO 01/89281 A2	11/29/01	Patent Cooperation Treaty				
	65.	WO 02/068654 A2	09/06/02	Patent Cooperation Treaty				
	66.	WO 92/21033	11/26/92	Patent Cooperation Treaty				
	67.	WO 96/01429	01/18/96	Patent Cooperation Treaty				
	68.	WO 96/03144 A1	02/08/96	Patent Cooperation Treaty				
	69.	WO 96/40209	12/19/96	Patent Cooperation Treaty				
	70.	WO 97/34613	09/25/97	Patent Cooperation Treaty				
	71.	WO 97/41440 A1	11/06/97	Patent Cooperation Treaty				
	72.	WO 98/13489	04/02/98	Patent Cooperation Treaty				
	73.	WO 98/14464	04/09/98	Patent Cooperation Treaty				
	74.	WO 98/40501 A1	09/17/98	Patent Cooperation Treaty				
	75.	WO 99/24596 A1	05/1999	Patent Cooperation Treaty				
	76.	WO 99/02183	01/21/99	Patent Cooperation Treaty				
	77.	WO 99/55730 A2	11/04/99	Patent Cooperation Treaty				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
---------------------	--

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MANNK.022C1	APPLICATION NO. Unassigned 10777053
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Simard, et al.	
	FILING DATE Concurrently herewith	GROUP Unassigned 1644

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
PV	78.	Aki et al., "Interferon-(Induces Different Subunit Organizations and Functional Diversity of Proteasomes," <i>J. Biochem.</i> , 115: 257-269 (1994)
	79.	Altuvia et al., "A structure-based algorithm to predict potential binding peptides to MHC molecules with hydrophobic binding pockets," <i>Human Immunology</i> , 58: 1-11 (1997)
	80.	An et al. "A Multivalent Minigene Vaccine, Containing B-Cell, Cytotoxic T-Lymphocyte, and T _H Epitopes from Several Microbes, Induces Appropriate Responses in Vivo and Confers Protection against More than One Pathogen", <i>J Virol</i> ; 71(3):2292-302 (1997).
	81.	Aria et al., "Isolation of Highly Purified Lysosomes from Rat Liver: Identification of Electron Carrier Components on Lysosomal Membranes", <i>J. Biochem.</i> , 110:541-7 (1991).
	82.	Arnold et al., "Proteasome subunits encoded in the MHC are not generally required for the processing of peptides bound by MHC class I molecules," <i>Nature</i> , 360: 171-174 (1992)
	83.	Ausubel et al., <i>Short Protocols in Molecular Biology</i> , Unit 11.2 (3d ed. 1997)
	84.	Ayyoub, et al., "Lack of tumor recognition by hTERT peptide 540-548-specific CD8 ⁺ T cells from melanoma patients reveals inefficient antigen processing," <i>Eur. J. Immunol.</i> , 31:2642-2651 (2001)
	85.	Bachmann et al., "In vivo vs. in vitro assays for the assessment of T- and B-cell function," <i>Curr. Opin. Immunol.</i> , 6:320-326 (1994).
	86.	Bettinotti et al., "Stringent Allele/Epitope Requirements for MART-1/Melan A Immunodominance: Implications for Peptide-Based Immunotherapy," <i>J. Immunol.</i> , 161: 877-889 (1998)
	87.	Boes et al., "Interferon γ Stimulation Modulates the Proteolytic Activity and Cleavage Site Preference of 20S Mouse Proteasomes," <i>J. Exp. Med.</i> , 179: 901-909 (1994)
	88.	Brown et al., "Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes," <i>Nature</i> , 353: 355-357 (1991)
	89.	Butterfield et al., "Generation of Melanoma-Specific Cytotoxic T Lymphocytes by Dendritic Cells Transduced with a MART-1 Adenovirus," <i>J. Immunol.</i> , 161: 5607-5613 (1998)
	90.	Carulli et al., "High Throughput Analysis of Differential Gene Expression", <i>J. Cellular Biochem Suppl.</i> , 30/31:286-96 (1998).
	91.	Chattergoon, et al., "Genetic Immunization: a new era in vaccines and immune therapeutics," <i>FASEB J.</i> , 11:753-763 (1997)
	92.	Chaux et al., "Identification of Five MAGE-A1 Epitopes Recognized by Cytolytic T Lymphocytes Obtained by In Vitro Stimulation with Dendritic Cells Transduced with MAGE-A1," <i>The Journal of Immunology</i> , 163: 2928-2936 (1999)
	93.	Cleland et al., "Design and developmental strategy", <i>Formulation and Delivery of Proteins and Peptides</i> , American Chemical Society Symposium Series, No. 567, (1994).
	94.	Davis, H. L., "Plasmid DNA expression systems for the purpose of immunization," <i>Current Opinion in Immunology</i> , 8: 635-640 (1997)
	95.	Dean et al., "Proteolysis in Mitochondrial Preparations and in Lysosomal Preparations Derived from Rat Liver", <i>Arch. Biochem. Biophys.</i> , 227:154-63 (1983).
	96.	Dean et al., "Sequence requirements for plasmid nuclear import," <i>Experimental Cell Research</i> , 253: 713-722 (1999)
	97.	DeGroot et al., "An Interactive Web Site Providing Major Histocompatibility Ligand Predictions: Application to HIV Research," <i>Aids Res. and Human Retrov.</i> , 13: 529-531 (1997)
V	98.	Dick et al., "Coordinated Dual Cleavages Induced by the Proteasome Regulator PA28 Lead to Dominant MHC Ligands," <i>Cell</i> , 86: 253-262 (1996)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MANNK.022C1	APPLICATION NO. Unassigned 10777053
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Simard, et al.	
		FILING DATE Concurrently herewith	GROUP Unassigned 1644

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
PV	99.	Dick, et al., "Proteolytic Processing of Ovalbumin and β -galactosidase by the Proteasome to Yield Antigenic Peptides," <i>J. of Immunology</i> , 152:3884-3894 (1994)
	100.	Driscoll et al., "MHC-linked LMP gene products specifically alter peptidase activities of the proteasome," <i>Nature</i> , 365: 262-264 (1993)
	101.	Durrant, L.G., "Cancer vaccines," <i>Anti-cancer drugs</i> , 8: 727-733 (1997)
	102.	Elliot et al., "Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein", <i>Cell</i> 88:223-233 (1997).
	103.	Escola et al., "Characterization of a Lysozyme-Major Histocompatibility Complex Class II Molecule-loading Compartment as a Specialized Recycling Endosome in Murine B Lymphocytes", <i>J. Biol. Chem.</i> 271:27360-65 (1996).
	104.	Falk et al., "Allele-specific Motifs Revealed by Sequencing of Self-peptides Eluted from MHC Molecules", <i>Nature</i> , 351:290-296 (1991).
	105.	Fang et al., "Expression of Vaccinia E3L and K3L Genes by a Novel Recombinant Canarypox HIV Vaccine Vector Enhances HIV-1 Pseudovirion Production and Inhibits Apoptosis in Human Cells", <i>Virology</i> 291(2):272-84 (2001).
	106.	Farrar et al., "The molecular cell biology of interferon- γ and its receptor," <i>Annu. Rev. Immunol.</i> , 11: 571-611 (1993)
	107.	Fayolle et al., "Delivery of Multiple Epitopes by Recombinant Detoxified Adenylate Cyclase of <i>Bordetella pertussis</i> Induces Protective Antiviral Immunity", <i>J Virol</i> 75(16):7330-8 (2001).
	108.	Fiette et al., "Theiler's virus infection of 129Sv mice that lack the interferon α/β or interferon γ receptors," <i>J. Exp. Med.</i> , 181: 2069-2076 (1995)
	109.	Firat et al., "Design of a Polyepitope Construct for the Induction of HLA-A*0201-restricted HIV 1-specific CTL Responses Using HLA-A*0201 Transgenic, H-2 Class I KO Mice", <i>Eur J Immunol</i> 31(10):3064-74 (2001).
	110.	Firat et al., "H-2 Class I Knockout, HLA-A2.1-Transgenic Mice: a Versatile Animal Model for Preclinical Evaluation or Antitumor Immunotherapeutic Strategies", <i>Eur J Immunol</i> 29(10):3112-21 (1999).
	111.	Firat et al., "Use of a Lentiviral Flap Vector for Induction of CTL Immunity Against Melanoma. Perspectives for Immunotherapy", <i>J Gene Med</i> ; 4(1):38-45 (2001).
	112.	Fomsgaard et al., "Induction of Cytotoxic T-cell Responses by Gene Gun DNA Vaccination with Minigenes Encoding Influenza A Virus HA and NP CTL-Epitopes", <i>Vaccine</i> 18(7-8):681-91 (2000).
	113.	Ford et al., "Protein Transduction: an Alternative to Genetic Intervention?", <i>Gene Ther.</i> 8:1-4, (2001).
	114.	Gaczynska et al., " γ -Interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes," <i>Nature</i> , 365: 264-267 (1993)
	115.	Gale et al., "Evidence that hepatitis C Virus resistance to interferon is mediated through repression of the PKR protein kinase by the oncostructural 5A protein," <i>Virology</i> , 230: 217-227 (1997)
	116.	Gariglio et al., "Therapeutic Uterine-Cervix Cancer Vaccines in Humans", <i>Arch Med Res</i> 29(4):279-84 (1998).
	117.	Gilbert et al., <i>Nat. Biotech.</i> 15:1280-1284, 1997
	118.	Gileadi et al., "Generation of an Immunodominant CTL Epitope is Affected by Proteasome Subunit Composition and Stability of the Antigenic Protein," <i>Am. Assoc. of Immunol.</i> , 163: 6045-6052 (1999)
	119.	Glynne et al., "A proteasome-related gene between the two ABC transporter loci in the class II region of the human MHC," <i>Nature</i> , 353: 357-360 (1991)
	120.	Groettrup et al., "A role for the proteasome regulator PA28a in antigen presentation," <i>Nature</i> , 381: 166-168 (1996)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MANNK.022C1	APPLICATION NO. Unassigned 10777053
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Simard, et al.	
		FILING DATE Concurrently herewith	GROUP Unassigned 1644

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
PV	121.	Gulukota et al., "Two complementary methods for predicting peptides binding major histocompatibility complex molecules," <i>J. Mol. Biol.</i> , 267: 1258-1267 (1997)
	122.	Gurunathan et al., "DNA vaccines: a key for inducing long-term cellular immunity," <i>Current Opinion in Immunology</i> , 12: 442-447 (2000)
	123.	Hammond et al., "Heavy Endosomes Isolated from the Rat Renal Cortex Show Attributes of Intermicrovillar Clefts", <i>Am. J. Physiol.</i> 267:F516-27 (1994).
	124.	Hanke et al., "DNA Multi-CTL Epitope Vaccines for HIV and <i>Plasmodium Falciparum</i> : Immunogenicity in Mice", <i>Vaccine</i> 16(4):426-35 (1998).
	125.	Heemskerk et al., "Enrichment of an Antigen-Specific T Cell Response by Retrovirally Transduced Human Dendritic Cells", <i>Cell Immunol.</i> 195(1):10-7 (1999).
	126.	Heim et al., "Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway," <i>Journal of Virology</i> , 73: 8469-8475 (1999)
	127.	Hirano et al., "Expression of a Mutant ER-retained Polytope Membrane Protein in Cultured Rat Hepatocytes Results in Mallory Body Formation", <i>Histochem. Cell Biol.</i> 117(1):41-53 (2002).
	128.	Huang et al., "Immune response in mice that lack the interferon-(receptor," <i>Science</i> , 259: 1742-1745 (1993)
	129.	Hung et al., "Improving DNA Vaccine Potency by Linking Marek's Disease Virus Type 1 VP22 to an Antigen", <i>J. Virol.</i> 76:2676-2682 (2002).
	130.	hypertext transfer protocol address syfpeithi.bmi-heidelberg.com/Scripts/MHCServer.dll/EpPredict.htm (4/3/03).
	131.	Inaba et al., "Identification of Proliferating Dendritic Cell Precursors in Mouse Blood," <i>J. Exp. Med.</i> 175:1157-67 (1992).
	132.	International Search Report from co-pending Application No. PCT/US01/13806
	133.	Jäger et al., "Granulocyte-macrophage-colony-stimulating Factor Enhances Immune Responses To Melanoma-associated Peptides <i>in Vivo</i> ", <i>Int. J Cancer</i> 67, 54-62 (1996).
	134.	Jager et al., "Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding Peptide Epitopes," <i>J. Exp. Med.</i> , 187: 265-270 (1998)
	135.	Kang et al., "Induction of Melanoma Reactive T Cells by Stimulator Cells Expressing Melanoma Epitope-Major Histocompatibility Complex Class I Fusion Proteins," <i>Cancer Res.</i> , 57: 202-205 (1997)
	136.	Kawakami et al., "The Use of Melanosomal Proteins in the Immunotherapy of Melanoma," <i>J. Immunother.</i> , 21:237-246 (1998)
	137.	Kawashima et al., "A Simple Procedure for the Isolation of Rat Kidney Lysosomes", <i>Kidney Int.</i> 54:275-8 (1998).
	138.	Kawashima et al., "The Multi-epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-associated Antigens Expressed on Solid Epithelial Tumors", <i>Human Immunology</i> 59:1-14 (1998).
	139.	Kelly et al., "Second proteasome-related gene in the human MHC class II region," <i>Nature</i> , 353:667-668 (1991).
	140.	Kittlesen et al., "Human Melanoma Patients Recognize an HLA-A1-Restricted CTL Epitope from Tyrosinase Containing Two Cysteine Residues: Implications for Tumor Vaccine Development," <i>J. Immunol.</i> , 160: 2099-2106 (1998)
	141.	Kuby, Janis, "Cell-mediated Immunity", <i>Immunology Chapter 15</i> (2d ed., W.H. Freeman and Company 1991).
	142.	Kündig et al., "Skin Test to Assess Virus-Specific Cytotoxic T-cell Activity," <i>Proc. Natl. Acad. Sci. USA</i> 89:7757-7761 (1992).
✓	143.	Kundig et al., "Fibroblasts as efficient antigen-presenting cells in lymphoid organs," <i>Proc. Natl. Acad. Sci.</i> , 268:1343-1347 (1995)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MANNK.022C1	APPLICATION NO. Unassigned 10777053
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Simard, et al.	
	FILING DATE Concurrently herewith	GROUP Unassigned 1644

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
PV	144.	Kündig et al., "On the Role of Antigen in Maintaining Cytotoxic T-cell Memory," <i>Proc. Natl. Acad. Sci. USA</i> 93:9716-23 (1996).
	145.	Larregina et al., "Direct Transfection and Activation of Human Cutaneous Dendritic Cells," <i>Gene Ther.</i> , 8:608-617 (2001)
	146.	Le et al., "Cytotoxic T Cell Polyepitope Vaccines Delivered by ISCOMs", <i>Vaccine</i> 19(32):4669-75 (2001).
	147.	Lee et al., "Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients," <i>Nature Medicine</i> , 5:677-685 (1999)
	148.	Leitner, et al., "DNA and RNA-based vaccines: principles, progress and prospects," <i>Vaccine</i> , 18:765-777 (2000)
	149.	Levy et al., "Using ubiquitin to follow the metabolic fate of a protein," <i>Proc. Natl. Acad. Sci. USA</i> , 93: 4907-4912 (1996)
	150.	Linette et al., "In Vitro Priming with Adenovirus/gp100 Antigen-Transduced Dendritic Cells Reveals the Epitope Specificity of HLA-A*0201-Restricted CD8+ T Cells in Patients with Melanoma," <i>J. Immunol.</i> , 164: 3402-3412 (2000)
	151.	Lisman et al., "A Separation Method by Means of Alteration of Mitochondrial and Synaptosomal Sedimentation Properties", <i>Biochem. J.</i> 178:79-87 (1979).
	152.	Liu et al., "Papillomavirus Virus-like Particles for the Delivery of Multiple Cytotoxic T Cell Epitopes", <i>Virology</i> 273(2):374-82 (2000).
	153.	Lofthus et al., "Peptides Derived from Self-Proteins as Partial Agonists and Antagonists of Human CD8+ T-cell Clones Reactive to Melanoma/Melanocyte Epitope MART1(27-35)," <i>Cancer Res.</i> , 11: 2433-2439 (1998)
	154.	Maksymowych et al., "Invasion by Salmonella typhimurium Induces Increased Expression of the LMP, MECL, and PA28 Proteasome Genes and Changes in the Peptide Repertoire of HLA-B27," <i>Infection and Immunity</i> , 66:4624-4632 (1998)
	155.	Marsh, M., "Endosome and Lysosome Purification by Free-flow Electrophoresis", <i>Methods Cell Biol.</i> 31:319-34 (1989).
	156.	Martinez et al., "Homology of proteasome subunits to a major histocompatibility complex-linked LMP gene," <i>Nature</i> , 353:664-667 (1991)
	157.	Mateo et al., "An HLA-A2 polyepitope vaccine for melanoma immunotherapy," <i>The Journal of Immunology</i> , 163: 4058-4063 (1999)
	158.	McCluskie, et al., "Route and Method of Delivery of DNA Vaccine Influence Immune Response in Mice and Non-Human Primates," <i>Molecular Medicine</i> , 5:287-300 (1999)
	159.	Meister et al., "Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences," <i>Vaccine</i> , 13: 581-591 (1995)
	160.	Melief, C. J., <i>Cancerlit</i> , Database Accession No. 1998625858, "Towards T-cell immunotherapy of cancer," Meeting Abstract (1996)
	161.	Miconnet et al., "Amino acid identity and/or position determine the proteasomal cleavage of the HLA-A *0201-restricted peptide tumor antigen MAGE-3," <i>The American Society for Biochemistry and Molecular Biology, Inc.</i> , page 20 (2000)
	162.	Missale et al., "HLA-A31-and HLA-Aw68-restricted Cytotoxic T cell Responses to a Single Hepatitis B Virus Nucleocapsid Epitope during Acute Viral Hepatitis," <i>J. Exp. Med.</i> , 177: 751-762 (1993)
	163.	Momburg et al., "Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation," <i>Nature</i> , 360: 174-177 (1992)
V	164.	Morel et al., "Processing of Some Antigens by the Standard Proteasome but not by the Immunoproteasome Results in Poor Presentation by Dendritic Cells," <i>Immunity</i> 12:107-117 (2000).
	165.	Morris et al., "A Peptide Carrier for the Delivery of Biologically Active Proteins into Mammalian Cells", <i>Nat. Biotech.</i> 19:1173-1176 (2001).

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MANNK.022C1	APPLICATION NO. Unassigned 10777053
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Simard, et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE Concurrently herewith	GROUP Unassigned 1644

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
PV	166. Moskopididis et al., "Immunobiology of Cytotoxic T-cell escape mutants of lymphocytic choriomeningitis virus," <i>Journal of Virology</i> , 69: 7423-7429 (1995)
	167. Murphy et al., "Higher-Dose and Less Frequent Dendritic Cell Infusions with PSMA Peptides in Hormone-Refractory Metastatic Prostate Cancer Patients," <i>The Prostate</i> , 43: 59-62 (2000)
	168. Nakabayshi et al., "Isolation and Characterization of Chicken Liver Lysosomes", <i>Biochem. Int.</i> 16:1119-25 (1988).
	169. NCBI Blast Accession Number NP_005502
	170. Noppen et al., "Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2, <i>Int. J. Cancer</i> , 87: 241-246 (2000)
	171. Normand et al., "Particle Formation by a Conserved Domain of the Herpes Simplex Virus Protein VP22 Facilitating Protein and Nucleic Acid Delivery", <i>J. Biol. Chem.</i> 276:15042-15050 (2001).
	172. Nussbaum et al., "Cleavage motifs of the yeast 20S proteasome β subunits deduced from digest of enolase 1," <i>Proc. Natl. Acad. Sci USA</i> , 95: 12504-12509 (1998)
	173. Oehen et al., "Antivirally protective cytotoxic T cell memory to lymphocytic choriomeningitis virus is governed by persisting antigen," <i>J. Exp. Med.</i> 176: 1273-1281 (1992)
	174. Oess et al., "Novel Cell Permeable Motif Derived from the PreS2-domain of Hepatitis-B Virus Surface Antigens, <i>Gene Ther.</i> 7:750-758 (2000).
	175. Ohshita et al., "Simple Preparation of Rat Brain Lysosomes and Their Proteolytic Properties", <i>Anal. Biochem.</i> 230:41-47 (1995).
	176. Oldstone et al., "Discriminated selection among viral peptides with the appropriate anchor residues: Implications for the size of the cytotoxic T-lymphocyte repertoire and control of viral infection," <i>Journal of Virology</i> , 69: 7423-7429 (1995)
	177. Oliveira et al., "A Genetic Immunization Adjuvant System based on BVP22-Antigen Fusion", <i>Hum. Gene Ther.</i> 12:1353-1359 (2001).
	178. Ortiz-Navarrete et al., "Subunit of the '20S proteasome (multicatalytic proteinase) encoded by the major histocompatibility complex," <i>Nature</i> , 353: 662-664 (1991)
	179. Overdijk et al., "Isolation of Lysosomes from Bovine Brain Tissue a New Zonal Centrifugation Technique", <i>Adv. Exp. Med. Biol./Enzymes of Lipid Metabolism</i> 101:601-10 (1978).
	180. Palmowski et al., "Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols", <i>J Immunol</i> 168(9):4391-8 (2002).
	181. Pantaleo et al., "Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection," <i>Proc. Natl. Acad. Sci.</i> , 94: 9848-9853 (1997)
	182. Parker et al., "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-chains," <i>J. Immunol.</i> 152:163-175 (1994).
	183. Pascolo et al., "HLA-A2.1-restricted Education and Cytolytic Activity of CD8 T Lymphocytes from β 2 Microglobulin (β 2m) HLA-A2.1 Monochain Transgenic H-2D ^b β 2m Double Knockout Mice" <i>J. Exp. Med.</i> 185:2043-2051 (1997).
	184. Perez-Diez et al., "Generation of CD8+ and CD4+ T-cell Response to Dendritic Cells Genetically Engineered to Express the MART-1/Melan-A Gene," <i>Cancer Res.</i> , 58: 5305-5309 (1998)
	185. Preckel et al., "Impaired Immunoproteasome Assembly and Immune Responses in PA28-I-Mice," <i>Science</i> , 286: 2162-2165 (1999)
	186. Puccetti et al., "Use of skin test assay to determine tumor-specific CD8+ T cell reactivity," <i>Eur. J. Immunol.</i> 24: 1446-1452 (1994)
V	187. Rammensee et al., "MHC ligands and peptide motifs: first listing," <i>Immunogenetics</i> , 41: 178-228 (1995)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MANNK.022C1	APPLICATION NO. Unassigned 10777053
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Simard, et al.	
	FILING DATE Concurrently herewith	GROUP Unassigned 1644

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
PV	188.	Rammensee et al., "Peptide motifs: amino acids in peptide-MHC interactions," <i>Landes Bioscience Austin Texas</i> , Chapter 4: 217-369 (1997)
	189.	Rammensee et al., "SYFPEITHI: Database for MHC ligands and peptide motifs," <i>Immunogenetics</i> , 50: 213-219 (1999)
	190.	Raz et al., "Preferential induction of a Th ₁ immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization," <i>Proc. Natl. Acad. Sci. USA</i> , 93: 5141-5145 (1996)
	191.	Reeves et al., "Retroviral Transduction of Human Dendritic Cells with a Tumor-Associated Antigen Gene," <i>Cancer Res.</i> , 56: 5672-5677 (1996)
	192.	Rehermann et al., "The Cytotoxic T Lymphocyte Response to Multiple Hepatitis B Virus Polymerase Epitopes During and After Acute Viral Hepatitis," <i>Journal of Exp. Medicine</i> , 181: 1047-1058 (1995)
	193.	Remington, <i>The Science and Practice of Pharmacy</i> , Nineteenth Edition, Chapters 86-88 (1985)
	194.	Ripalti et al., "Construction of Polyepitope Fusion Antigens of Human Cytomegalovirus ppUL32: Reactivity with Human Antibodies", <i>J Clin Microbiol</i> 32(2):358-63 (1994).
	195.	Roberts et al., "Prediction of HIV Peptide Epitopes by a Novel Algorithm," <i>Aids Research and Human Retroviruses</i> , 12: 593-610 (1996)
	196.	Rock et al., "Degradation of cell proteins and the generation of MHC class I-presented peptides," <i>Annu. Rev. Immunol.</i> , 17: 739-779 (1999)
	197.	Roman et al., "Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants," <i>Nature Medicine</i> , 3: 849-854 (1997)
	198.	Rosmorduc et al., "Inhibition of interferon-inducible MxA protein expression by hepatitis B virus capsid protein," <i>Journal of General Virology</i> , 80: 1253-1262 (1999)
	199.	Ryan et al., "A model for nonstoichiometric, cotranslational protein scission in eukaryotic ribosomes," <i>Bioorganic Chemistry</i> , 27: 55-79 (1999)
	200.	Ryser et al., "The Cellular Uptake of Horseradish Peroxidase and its Poly(Lysine) Conjugate by Cultured Fibroblasts Is Qualitatively Similar Despite a 900-Fold Difference in Rate", <i>J. Cell Physiol.</i> 113:167-178 (1982).
	201.	Salmi et al., "Tumor endothelium selectively supports binding of IL-2 propagated tumor-infiltrating lymphocytes," <i>The Journal of Immunology</i> , 154: 6002-6012 (1995)
	202.	Santus et al., "Osmotic Drug Delivery: A Review of the Patent Literature," <i>Journal of Controlled Release</i> , 35:1-21 (1995).
	203.	Sato et al., "Immunostimulatory DNA sequences necessary for effective intradermal gene immunization," <i>Science</i> , 273: 352-354 (1996)
	204.	Schirle et al., "Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens," <i>Journal of Immunological Methods</i> , 257: 1-16 (2001)
	205.	Schmid et al., "Isolation of Functionally Distinct Endosome Subpopulations by Free-Flow Electrophoresis", <i>Prog. Clin. Biol. Res./Cell-Free Analysis of Membrane Traffic</i> 270:35-49 (1988).
	206.	Schneider, et al., "Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1," <i>Int. J. Cancer</i> , 75(3):451-458 (1998)
	207.	Schwartz, J.J. & Zhang, S., "Peptide-mediated cellular delivery", <i>Curr. Opin. Mol. Ther.</i> 2:162-167 (2000).
	208.	Seipelt et al., "The Structures of Picornaviral Proteinases," <i>Virus Research</i> 62:159-68 (1999).
✓	209.	Sewell et al., "IFN- γ Exposes a Cryptic Cytotoxic T Lymphocyte Epitope in HIV-1 Reverse Transcriptase," <i>J. Immunol.</i> , 162: 7075-7079 (1999)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MANNK.022C1	APPLICATION NO. Unassigned 10777053
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Simard, et al.	
	FILING DATE Concurrently herewith	GROUP Unassigned 1644

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
PV	210.	Sheldon et al., "Loligomers: Design of <i>de novo</i> Peptide-based Intracellular Vehicles", <i>Proc. Natl. Acad. Sci. USA</i> 92:2056-2060 (1995).
	211.	Shen et al., "Conjugation of Poly-L-lysine to Albumin and Horseradish Peroxidase: A Novel Method of Enhancing the Cellular Uptake of Proteins", <i>Proc. Natl. Acad. Sci. USA</i> 75:1872-1876 (1978).
	212.	Sijts et al., "Efficient Generation of a Hepatitis B Virus Cytotoxic T Lymphocyte Epitope Requires the Structural Features of Immunoproteasomes," <i>Journal of Exp. Medicine</i> , 191: 503-513 (2000)
	213.	Smith et al., "Human Dendritic Cells Genetically Engineered to Express a Melanoma Polyepitope DNA Vaccine Induce Multiple Cytotoxic T-Cell Responses", <i>Clin Cancer Res</i> ; 7(12):4253-61 (2001).
	214.	Smith, "The polyepitope approach to DNA vaccination", <i>Curr Opin Mol Ther</i> 1(1):10-5 (1999).
	215.	Speiser et al., "Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy," <i>Journal Exp. Medicine</i> , 186: 645-653 (1997)
	216.	Stauss et al., "Induction of Cytotoxic T Lymphocytes with Peptides In Vitro: Identification of Candidate T-cell Epitopes in Human Papilloma," <i>Proc. Natl. Acad. Sci</i> , 89: 7871-7875 (1992)
	217.	Steinmann et al., "The Dendritic Cells System and Its Role in Immunogenicity," <i>Ann. Rev. Immunol.</i> 9:271-96 (1991).
	218.	Street et al., "Limitations of HLA-transgenic Mice in Presentation of HLA-restricted Cytotoxic T-cell Epitopes from Endogenously Processed Human Papillomavirus type 16 E7 Protein", <i>Immunology</i> 106(4):526-36 (2002).
	219.	Stromhaug et al., "Purification and Characterization of Autophagosomes from Rat Hepatocytes", <i>Biochem. J.</i> 335:217-24 (1998).
	220.	Sturmliolo et al., "Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices," <i>Nature Biotechnology</i> , 17: 555-561 (1999)
	221.	Suhrbier A, "Multi-epitope DNA Vaccines", <i>Immunol Cell Biol</i> 75(4):402-8 (1997).
	222.	Taylor et al., "Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein," <i>Science</i> , 285: 107-110 (1999)
	223.	Thomson et al., "Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination", <i>J Immunol</i> 160(4):1717-23 (1998).
	224.	Thomson et al., "Minimal Epitopes Expressed in a Recombinant Polyepitope Protein are Processed and Presented to CD8 Cytotoxic T cells: Implications for Vaccine Design", <i>Proc Natl Acad Sci USA</i> 92(13):5845-9 (1995).
	225.	Thomson et al., "Recombinant Polyepitope Vaccines for the Delivery of Multiple CD8 Cytotoxic T Cell Epitopes", <i>J Immunol</i> 157(2):822-6 (1996).
	226.	Tjoa et al., "Evaluation of Phase I/II Clinical Trials in Prostate Cancer with Dendritic Cells and PSMA Peptides," <i>The Prostate</i> , 36: 39-44 (1998)
	227.	Toes et al., "Discrete Cleavage Motifs of Constitutive and Immunoproteasomes Revealed by Quantitative Analysis of Cleavage Products", <i>J. Exp. Med.</i> 194:1-12 (2001).
	228.	Toes et al., "Protective Anti-tumor Immunity Induced by Vaccination with Recombinant Adenoviruses Encoding Multiple Tumor-associated Cytotoxic T Lymphocyte Epitopes in a String-of-beads Fashion", <i>Proc Natl Acad Sci USA</i> 94(26):14660-5 (1997).
	229.	Türeci et al., "Serological Analysis of Human Tumor Antigens: Molecular Definition and Implications," <i>Molecular Medicine Today</i> 3:342 (1997).
	230.	Twu et al., "Transcription of the human beta interferon gene is inhibited by hepatitis B virus," <i>Journal of Virology</i> , 63: 3065-3071 (1989)
V	231.	Valmori et al., "Induction of Potent Antitumor CTL Responses by Recombinant Vaccinia Encoding a Melan-A Peptide Analogue," <i>J. Immunol.</i> , 164: 1125-1131 (2000)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MANNK.022C1	APPLICATION NO. Unassigned 10777053
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Simard, et al.	
		FILING DATE Concurrently herewith	GROUP Unassigned 1644

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
PV	232.	Van den Eynde et al., "Differential Processing of Class-I-Restricted Epitopes by the Standard Proteasome and the Immunoproteasome," <i>Curr. Opinion in Immunol.</i> , 13: 147-153 (2001)
	233.	Van Kaer et al., "Altered Peptidase and Viral-Specific T Cell Response in LMP2 Mutant Mice," <i>Immunity</i> 1: 533-541 (1994)
	234.	Vitiello et al., "Comparison of Cytotoxic T lymphocyte responses induced by peptide or DNA immunization: implications on immunogenicity and immunodominance," <i>Euro. Jr. Immunol.</i> , 27: 671-678 (1997)
	235.	Vonderheide et al., "Characterization of HLA-A3-restricted Cytotoxic T Lymphocytes Reactive Against the Widely Expressed Tumor Antigen Telomerase", <i>Clin Cancer Res</i> 7(11):3343-8 (2001).
	236.	Wang et al., "Phase I Trial of a MART-1 Peptide Vaccine with Incomplete Freund's Adjuvant for Resected High-Risk Melanoma," <i>Clin. Cancer Res.</i> , 10: 2756-2765 (1999)
	237.	Ward et al., "Development and Characterisation of Recombinant Hepatitis Delta Virus-like Particle", <i>Virus Genes</i> 23(1):97-104 (2001).
	238.	Wattiaux et al., "Isolation of Rat Liver Lysosomes by Isopycnic Centrifugation in a Metrizamide Gradient", <i>J. Cell Biol.</i> 78:349-68 (1978).
	239.	Whitton et al., "A "String-of-Beads" Vaccine, Comprising Linked Minigenes, Confers Protection from Lethal-Dose Virus Challenge", <i>J Virol</i> 67(1):348-52 (1993).
	240.	Williams et al., "Isolation of a Membrane-Associated Cathespin D-like Enzyme from the Model Antigen Presenting Cell, A20, and Its Ability to Generate Antigenic Fragments from a Protein Antigen in a Cell-Free System", <i>Arch. Biochem. Biophys.</i> 305:298-306 (1993).
	241.	Woodberry et al., "Immunogenicity of a Human Immunodeficiency Virus (HIV) Polytope Vaccine Containing Multiple HLA A2 HIV CD8 Cytotoxic T-Cell Epitopes", <i>J Virol</i> 73(7):5320-5 (1999).
	242.	Yamada et al., "A Simple Procedure for the Isolation of Highly Purified Lysosomes from Normal Rat Liver" <i>J. Biochem.</i> 95:1155-60 (1984).
	243.	Yang et al., "Proteasomes Are Regulated By Interferon (: Implications For Antigen Processing," <i>Proc. Natl. Acad. Sci.</i> , 89: 4928-4932 (1992)
	244.	Yewedell, et al., " MHC-Encoded Proteasome Subunits LMP2 and LMP7 Are Not Required for Efficient Antigen Presentation," <i>J. Immunology</i> 1994, 152:1163-1170 (1994)
	245.	Young et al., "Dendritic Cells as Adjuvants for Class I Major Histocompatibility Complex-restricted Anti-tumor Immunity," <i>J Exp Med</i> 183:7-11 (1996).
	246.	Zajac et al., "Enhanced Generation of Cytotoxic T Lymphocytes Using Recombinant Vaccinia Virus Expressing Human Tumor-Associated Antigens and B7 Costimulatory Molecules," <i>Cancer Res.</i> , 58: 4567-4571 (1998)
	247.	Zajac et al., "Generation of Tumoricidal Cytotoxic T Lymphocytes from Healthy Donors after In Vitro Stimulation with a Replication-Incompetent Vaccinia Virus Encoding MART-1/Melan-A 27-35 Epitope," <i>Int. J. Cancer</i> , 71: 491-496 (1997)
	248.	Zhai et al., "Antigen-Specific Tumor Vaccines. Development and Characterization of Recombinant Adenoviruses Encoding MART1 or gp100 for Cancer Therapy," <i>J. Immunol.</i> , 156: 700-710 (1996)
	249.	Zipkin, I., "Cancer vaccines," <i>Bio Century</i> , 6: A1-A6 (1998)
	250.	International Search Report re International Application No. PCT/US03/26231 Date of Mailing of International Search Report: 02 December 2003
↓	251.	International Search Report re International Application No. PCT/US02/35582 Date of Mailing of International Search Report: 14 November 2003

S:\DOCS\MTM\MTM-5701.DOC\dmr 020904

EXAMINER	/F. Pierre Vandervegt/	DATE CONSIDERED	10/01/2006
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			